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Abstract
Glycans, or complex carbohydrates, are a ubiquitous class of biological molecules which impinge
on a variety of physiological processes ranging from signal transduction to tissue development and
microbial pathogenesis. In comparison to DNA and proteins, glycans present unique challenges to
the study of their structure and function owing to their complex and heterogeneous structures and
the dominant role played by multivalency in their sequence-specific biological interactions.
Arising from these challenges, there is a need to integrate information from multiple
complementary methods to decode structure-function relationships. Focusing on acidic glycans,
we describe here key glycomics technologies for characterizing their structural attributes,
including linkage, modifications, and topology, as well as for elucidating their role in biological
processes. Two cases studies, one involving sialylated branched glycans and the other sulfated
glycosaminoglycans, are used to highlight how integration of orthogonal information from diverse
datasets enables rapid convergence of glycan characterization for development of robust structure-
function relationships.
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1. Introduction
Glycans, largely located at the interface between the cell surface and extracellular matrix,
modulate cellular functions through specific, non-covalent interactions with growth factors,
cytokines, enzymes, receptors, and other proteins present in this environment [1]. Glycans,
depending on their structure and location, positively or negatively modulate cell growth and
development [1–5], immunity [6–8], cell-cell interactions [9–11], tumor growth and
metastasis [12–17], and microbial pathogenesis [18–20], among other processes. In addition
to affecting physiology by binding proteins, glycans also affect the structural properties of
the molecules to which they are conjugated (either covalently or non-covalently), such as by
aiding folding, increasing solubility and stability, and influencing the clearance rate of
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proteins [21]. To highlight but one example, sialylation of erythropoietin is known to
profoundly affect its in vivo half-life. Hypersialylation by, for instance, adding additional
glycosylation sites results in creation of a pharmaceutical agent that can be given on a less
frequent (more convenient) dosing schedule due to its extended residence in the circulation
[22]. Conversely, desialylation of erythropoietin results in a molecule that has a very rapid
disappearance from the bloodstream, but one that crosses into the central nervous system
and has marked neuroprotective effects [23].
As with the erythropoietin example, glycans are typically found as covalent conjugates
either to lipids (glycolipids) or to proteins (glycoproteins), although unconjugated forms are
known to exist (e.g., hyaluronan). Broadly, glycans can be classified as either branched or
linear (Figure 1). Branched glycans are present as N- and O-linked glycosylation on
glycoproteins and on glycolipids, whereas linear glycans attached to proteins are mostly
glycosaminoglycans (GAGs), which are polysaccharide chains made up of disaccharide
units with differential sulfation and are typically O-linked to a protein core [1, 24]. In
mammals, glycolipids are predominantly present as glycosphingolipids, which are
characterized by the presence of branched or linear glycans that can be negatively charged
(sialylated or sulfated) or neutral (no charged groups) [25].
Advancements in tools to decipher glycan fine structure and to define their physiological
function have helped mature the field of glycomics, in part by addressing many of the
challenges of glycan structure-function characterization (Table 1). Glycans have multiple
potential structural elements, such as the branching pattern, linkage between
monosaccharides, and site of attachment, which result in higher complexity and diversity
than is typically found in proteins and nucleic acids. This structural diversity is further
complicated by glycan biosynthesis, a non-proofreading, non-template-driven process which
involves the concerted action of a variety of glycosyltransferases and glycosidases with
tissue-, developmental- and metabolic-dependent expression and activity [2, 24, 26]. In
terms of function, glycans are presented in physiological systems as an ‘ensemble’ of similar
structures in which glycan-protein interactions achieve high specificity and high affinity
through multivalent interactions (avidity) [27, 28]. Compared to proteins, capturing these
key properties of glycan presentation complicates the ability to accurately and specifically
measure glycan binding events. In fact, one of the key challenges in glycomics is to be able
to address this notion that an ensemble of structures together modulate a biological function,
and that all information is not necessarily encoded by sequence alone, with there being both
finer and coarser determinants to activity.
Substantial progress in addressing many of the challenges of glycomics has been made in
key areas, including analytical technologies [29–38], synthesis methods [39–43], glycan
functional tools (including knockout mice) [44–46], specialized databases that store
glycomics-specific information and computational tools [47–50]. Advances in many of these
areas have enabled the scientific community to probe glycan structure-function relationships
in unprecedented ways. Indeed, a variety of highly sensitive analytical methods, including
mass spectrometry (MS), high performance liquid chromatography (HPLC), LC/MS,
capillary electrophoresis (CE), nuclear magnetic resonance (NMR) spectroscopy, and lectin
arrays, provide means to probe many fine structural attributes of carbohydrates (Table 2).
However, each particular methodology has its strengths and weaknesses, especially in terms
of the information content (i.e., structural attributes) which can be readily measured from the
approach. The use of multiple methodologies for structural and functional glycomics
overcomes these constraints but often leads to large, complex and diverse datasets,
necessitating the integration of results from multiple complementary tools. Moreover, as
new technologies have opened additional avenues for glycobiology-driven discovery, the
need for integrating diverse datasets has expanded, especially given the non-binary
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relationship between sequence and function. Thus, this review will focus on how integration
of information content across multiple lines of inquiry has enabled - (1) convergence in
glycan characterization in a more rapid manner than is possible using any one individual
method as well as (2) development of robust structure-function relationships.
Numerous reviews have expertly outlined the use of particular analytical techniques for
glycan structural determination, including MS [31, 51–58], NMR [32, 59–63], and lectins
[33, 64–73]. To complement these reviews, we focus here on the role of integrated efforts
towards determination of structure and structure-function relationships. This is best
exemplified, in our opinion, by focusing on the class of acidic glycans where multiple recent
advances have provided key insights into structure and biology and highlight the necessity
of integrating information from multiple datasets to elucidate structure-function
relationships. Within this review, we will focus on three major groups of acidic glycans: (1)
sialylated glycans that often are present as lipid or protein conjugates (N- and O-linked), (2)
sulfated/phosphorylated glycoconjugates, and (3) extended sulfated glycans O-linked to a
protein core within the context of proteoglycans.
2. Structural elucidation of acidic glycans
Biological functions of glycans are mediated largely by their interactions with glycan-
binding proteins (GBPs), and the specificity of these interactions is in turn regulated by the
structural recognition of glycan motifs in the context of multivalent glycan-GBP
interactions. Much of the structural variation on cells exists in the sugar sequence of the
terminal residues and with modifications such as acetylation, sulfation, and phosphorylation
[74–76]. Acidic motifs, represented by carboxylated (sialic acids and uronic acids), sulfated
(GAGs and branched glycans with sulfation), and phosphorylated substituents (Figure 2),
are often, but not always, located on the terminal sugars of glycan chains and play a
dominant role in the regulation of many diverse biological activities. For example, as a
result of their typical terminal location and negative charge, sialylated motifs extensively
participate in varied physiological and pathologies processes, including immune
surveillance, cell adhesion, proliferation, apoptosis, development, and as attachment ligands
for a range of pathogenic bacteria, protozoa, fungi, and viruses (reviewed in [10, 77–79]).
There are more than 50 structural variations of the sialic acid monosaccharide in nature, and
further layers of complexity can be considered in terms of varied linkages, neighboring
residues, presentation (e.g., branching diversity), and spatial organization along cell surfaces
[80]. Other anionic modifications, including sulfation and phosphorylation, also play a
pivotal role in the regulation of many biological processes. This can perhaps be best
illustrated with GAGs, in which subtle changes in the amount and position of sulfates
provide a “sulfation code” that largely governs specificity of protein-GAG interactions [81–
84].
The diverse functions mediated by acidic glycans underscore the need to elucidate the
structure-function relationships of this class of carbohydrates, and in particular, understand
the fine structural features which govern their specificity of interactions. Measurement of
acidic glycans, however, by “typical” analytical methods, even those that have proven useful
for global glycomics analyses, is often complicated by the fact that acidic groups are labile
in many sample workup and analytical methods, such as depolymerization (e.g., for CE- and
MS-based compositional analysis [85]), derivatization (e.g., acidic reductive amination for
fluorescence detection [86]) and analysis (e.g., mass spectrometry) [87, 88]. A second,
related issue is that acidic groups on glycans strongly bind to monovalent and divalent
cations, such as calcium and sodium, which further complicates their analysis by MS and
NMR-based techniques through the creation of multiple adducts with different charge states.
Moreover, their highly charged character limits the use of traditional chromatography, such
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as reversed phase HPLC, which is the mode of choice for many advanced hyphenated
techniques such as LC/MS.
2.1 Mass spectrometry-based approaches
Paralleling proteomics and lipidomics, MS has emerged as a corner stone for high
throughput and sensitive structural characterization of glycans. As in the case in other –
omics fields, combining electrospray ionization (ESI) with matrix-assisted laser desorption
ionization (MALDI) often provides complementary information and enables a broader
coverage of complex samples than either method alone. Acidic groups on glycans, however,
can undergo significant fragmentation and loss of their acidic moieties during typical
MALDI-MS conditions [87–89]. The acidic proton of anionic glycans also substantially
exchanges with alkali metal cations, leading to the formation of metal adducts which
increase the complexity of MS spectra as well as reduce signal intensity [90]. Moreover,
acidic glycans analyzed in the positive-ion mode are usually suppressed due to their low
ionization efficiency compared to their neutral counterparts. As a result, negative-ion mode
is typically used, however, a loss of sensitivity occurs if negative-ion mode is exclusively
used for glycan mixtures containing neutral and acidic carbohydrates, making quantification
difficult [91].
Many of the challenges associated with MALDI-MS analysis of acidic glycans have been
addressed with different strategies, including stabilizing acidic groups and improving
ionization/sensitivity. The labile nature of acidic glycans can be partially overcome using
matrices for softer ionization [92–95], atmospheric-pressure conditions [96], and additives
such as basic peptides [97] or spermine [98]. The use of nafion [99] or cation exchange
resins can also be effectively used to remove complicating counter ions, thus improving
sensitivity and easing analysis of spectra.
Derivatization of native glycans also represents an effective strategy to solve issues with
acidic carbohydrates. However, due to sample loss that frequently accompanies workup
steps, derivatization may not be appropriate for certain samples containing acidic glycans
due to their low abundance. Notably, derivatization methods such as permethylation
improve sensitivity, enable the simultaneous analysis of both neutral and acidic glycans in
positive-ion mode, increase the useful information that can be obtained from fragmentation
experiments, and improve the accuracy of quantification [100, 101]. While permethylation is
effective in stabilizing sialylated glycans, the method (in its most routinely used form
developed by Ciucanu and Kerek [102]) causes the undesired effect of removing some
acidic substituents, including sulfates and phosphates [103]. Thus, for many complex glycan
mixtures that contain diverse acidic glycan motifs, permethylation will cause the loss of
structural information, potentially destroying critical motifs. Other derivatization techniques,
such as modified permethylation [104], methyl ester formation [90], amidation [105] and
newer methods such as double permethylation [106], have helped address many of the limits
of “typical” permethylation techniques, though these methods may require more involved
processing steps and may lead to greater sample losses and accordingly, sample bias.
ESI-MS provides an alternative approach with the notable advantages of less fragmentation
(softer ionization) and improved ionization efficiency for acidic glycans, thus making it a
preferred analytical platform for analysis of many acidic glycans, particularly sulfated
oligosaccharides [89, 107, 108]. However, glycan sequencing by ESI-MS/MS of native
samples run in negative mode typically provides incomplete linkage-specific cleavage ions
[109, 110]. Introduction of newer fragmentation techniques, including electron capture
dissociation, have proven useful for the analysis of glycoproteins/peptides, particularly ones
containing acidic modifications. Permethylation of samples, in turn, may be used to improve
information content from fragmentation experiments, though limitations such as removal of
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sulfates and phosphates remain. ESI-MS also leads to the formation of multiply charged
ions, causing increased complexity in spectra analysis and reduced sensitivity. Due to the
higher sensitivity of ESI-MS to the presence of sample contaminants such as salts and
detergents (which are often used to extract glycoconjugates at the cell surface), experiments
and workup strategies are limited to those which provide sufficient sample cleanup.
In terms of the wealth of information content associated with the technique, its sensitivity,
and its ability to link both structural determination and quantification, MS has been and will
likely continue to be one of the primary methods employed to analyze glycan structures.
However, in our opinion, despite the advances that have been made, MS-related
technologies require supplementation with other techniques in the context of a larger,
integrated approach. This is, at least in part, due to the fact that assignment of glycosidic
linkage and isomeric position of acidic groups, such as sulfates, is very difficult using MS
strategies by themselves. Fortunately, the field has advanced a series of techniques that
enable this analysis very precisely. Use of orthogonal analytical techniques enables one to
arrive at detailed structural information in a more rapid, unbiased, and accurate manner than
is possible through the use of any single analytical methodology.
2.2 NMR
NMR is a powerful technology for the characterization of many structural attributes of
glycans. 1H and 13C chemical shifts of carbohydrate samples can be used to define features
such as composition, linkage, anomeric configuration, and presence of chemical
modifications [32, 60, 62]. Notably, NMR is non-destructive in nature, and thus sample
material can be recovered for other subsequent structural or functional studies. While NMR
can be effectively used for detailed and complete structural characterization of smaller
oligosaccharides, such an analysis requires a high level of purity (>95%), which may be
challenging or cause the loss of minor components during separation schemes. In such cases,
NMR is an efficient tool to obtain quantitative properties and constraints on glycan mixtures
with relatively small amounts of material. For example, 1H-NMR with as little as 100
micrograms of sample material has been used to characterize the ratio of specific linkages
and branching patterns as well as the presence and absence of specific sugars (with their
linkages) [111], information that, by MS methods alone, would require involved MS/MS
techniques with complex peak analysis. To assist researchers in the assignment of glycan
structures and features based on NMR data, the characteristic NMR chemical shifts and
coupling constants of various glycans in literature have been compiled in accessible
databases such as at the Glycosciences.de portal (http://www.glycosciences.de/sweetdb/)
[112] and CASPER (http://www.casper.organ.su.se/casper/) [113–115], thus improving the
accessibility of NMR as a tool for glycoscientists.
2.3 Lectins and glycan-modifying enzymes
The specificity of glycan-modifying enzymes and lectins make them useful tools for
structural characterization studies as well as to directly aid other analytical techniques by
providing an additional layer of information content. For example, one approach to decipher
linkage information has been to employ exoglycosidases that specifically cleave
monosaccharides with defined linkages from the nonreducing end of a glycan. The HPLC
chromatographic profile of the parent glycan sample and the shifts in peaks which result
from treatment with the exoglycosidases are matched with reference chromatographic
profiles of known glycan structures using software tools to derive the exact structure of
glycans in the sample [116–118]. Utilizing lectins for affinity-based chromatographic and
electrophoretic methods has proved useful due to their unique selectivity and resolution in
separation/fractionation studies as well as for enrichment of glycans with specific motifs
which may be otherwise difficult to characterize, such as specific sialylated glycan and
Robinson et al. Page 5
Electrophoresis. Author manuscript; available in PMC 2013 August 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
glycoprotein populations [119–121]. In the case of GAGs, the selectivity of GAG-degrading
enzymes, such as heparinases, chondroitinases, etc., has proven to be a key tool for the
controlled and precise depolymerization or modification of GAG chains, thus increasing the
information content from analytical assays. Indeed, informatics-based methods using GAG-
degrading enzymes coupled with analytical techniques have been developed to capture the
information density of GAGs and to enable the application of data from a combination of
tools as constraints to sequence GAGs [122, 123].
Technologies incorporating lectins have been developed for directly probing structural
attributes of glycan samples based on the glycan determinants (motifs) specifically
recognized by lectins. Recent increased availability of recombinant lectins as well as
knowledge of their binding specificity through glycan array studies have helped facilitate
development of lectin microarrays, which contain a panel of lectins immobilized at high
density to probe binding of carbohydrate analytes in high throughput (reviewed in [67–69,
124]). In addition to array platforms, lectins have been effectively used for probing
biological samples to define the presence of specific glycan moieties. Importantly, these
techniques enable analysis of glycans within their biological contexts. The functions of
glycans depend in part on their physiological localization and context for access to proximal
molecules, and thus lectin staining of cells and tissues helps decode glycan structure-
function relationships by defining differences in localization as opposed to strictly structural
composition after isolation [125, 126]. Indeed, this fact has been exploited in pathology,
where reagents used to identify pathologic conditions include some that recognize specific
glycan or glycoconjugate structures [127–130].
2.4 Databases and computational tools
In addition to experimental advances, several databases and computational tools have been
developed to facilitate assignment of the most likely set of structures or structural attributes
that satisfy one or more analytical datasets (as summarized in recent reviews and book
chapters [47, 112, 131–137]). In the case of a typical high throughput dataset such as a
MALDI-MS profile of glycans isolated from cells/tissues, tools such as GlycoMod [138]
and Cartoonist [139] have been developed to assign a set of compositions and/or glycan
topologies for a given mass peak based on biosynthetic constraints.
The next level of characterization involves matching the fragmentation patterns of the parent
ion from the MS2 (and possibly higher order MS3 to MSn) data to reference datasets and
deducing the most likely glycan structures based on these data. The common reference
datasets are those derived from the theoretical fragmentation of known glycan structures
stored in different glycan structure databases [50, 135, 140]. Examples of tools developed
for this purpose include Glyco-Search-MS (http://www.glycosciences.de/sweetdb/start.php?
action=form_ms_search) [141] and GlycoWorkbench (http://www.glycoworkbench.org/)
[142, 143]. Other approaches that have been utilized to create reference datasets include
generation of possible theoretical fragments or compositions from a parent mass ion. The set
of compositions is then used to generate possible glycan structures (using biosynthesis rules
in some cases) whose theoretical fragmentation pathways are matched with the MSn data
tree. Reference datasets have also been generated from experimental fragmentation profiles
of well-characterized glycan structures or oligosaccharide fragments [144, 145]. The STAT
[146], StrOligo [147] and OSCAR [148] programs use these approaches.
Enzymes involved in glycan modification have been annotated and classified in many
databases including GlycoGene DataBase (GGDB) (http://riodb.ibase.aist.go.jp/rcmg/
ggdb/), Carbohydrate-Active enZYme Database (CAZy) (http://www.cazy.org/), Kyoto
Encyclopedia for Genes and Genomes (KEGG) (http://www.genome.jp/kegg/glycan/
GT.html) and Consortium for Functional Glycomics (CFG) (http://
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www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/geMolecule.jsp).
Detailed information resources on plant, animal and microbial lectins have been captured
and annotated in many databases including Lectines 3D (http://www.cermav.cnrs.fr/
lectines/), genomics resources for animal lectins (http://www.imperial.ac.uk/research/
animallectins/), CFG GBP molecule pages (http://www.functionalglycomics.org/glycomics/
molecule/jsp/gbpMolecule-home.jsp), and SugarBindDB (http://sugarbind.expasy.org/
sugarbind/). The availability of these resources facilitate assignment of glycan structures
based on their biosynthetic pathways and also screening or isolating glycans based on the
binding specificity of specific motifs contained in these glycans to different lectins.
Taken together, it is clear that there have been significant advances in both experimental and
computational approaches to address glycan structural complexity and provide insights into
important structure-function relationships. Ultimately, given the set of analytical tools that
have been developed, it is likely the case that the nuances of a specific biology will
determine our ability to derive important insights, rather than the lack of effective tools to
interrogate them.
3. Integrating structure with functional glycomics datasets
Characterization of glycan fine structural features by analytical methods is but the first
(necessary) step towards decoding structure-function relationships for glycans. Several
additional technologies described in the following section have recently come to the
forefront in terms of critically informing glycan structure-function determination.
3.1 Glycogene analysis tools
The regulation of genes whose protein products are involved in glycan synthesis and glycan-
protein interaction contributes to understanding of glycan structural diversity and function in
biological systems. Efforts to understand expression of glycogenes are thus an important
facet of glycomics research [45, 149]. Commercially available gene microarrays have been
observed to have incomplete representation, poor annotation and restricted sensitivity for
low abundance transcripts that are commonly involved in glycan biosynthesis [149–152]. To
address these limitations, microarrays specific for understanding the transcriptional
regulation of the glycome have been developed [150, 151]. Such tools enable clear and
accurate signal detection of genes representing GBPs and glycoenzymes, including enzymes
that encode for transfer and removal of acidic glycan motifs, such as sulfotransferases,
sialyltransferases, and sulfatases. Gene manipulation tools, such as transgenic and knockout
animal models, have aided discernment of the role of glycan motifs in complex biology [46,
153–155]. Indeed, conditional disruption of a heparan sulfate (HS)--polymerizing gene
demonstrates the essential role of HS in mammalian brain morphogenesis [156], and
transgenic models disrupting activity of GNE, whose protein product catalyzes the first two
steps of sialic acid biosynthesis, emphasized the fundamental role of sialylation for early
development in mice and normal renal function [157, 158].
3.2 Synthetic glycans
Synthetic glycans are also a critical component towards precisely defining glycan-protein
interactions through provision of chemically defined oligosaccharides for binding assays and
other biological readouts [41–45, 159, 160]. Strategies for chemical synthesis of
oligosaccharides, particularly those representing terminal motifs of N- and O-linked glycans
and glycolipids, have seen significant advancements during the previous decade [159, 161],
however the labile nature and diversity of acidic substituents substantially challenges purely
chemical approaches to generate synthetic sialosides and sulfated oligosaccharides,
including GAGs. Discovery of the genes involved in formation of acidic glycan structures,
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including sulfotransferases and sialyltransferases, has enabled development of
chemoenzymatic synthesis tools for defined glycan structures and offers a promising
synthetic strategy [77, 162–168]. To facilitate appropriate presentation of synthetic
oligosaccharides for investigation of glycan interactions with their protein partners, scaffolds
have been engineered for polyvalent glycan presentation with diverse multivalent
architectures: low-molecular weight molecules, polymers (e.g., polyglutamic acid and
polyacrylamide), dendrimers, liposomes, proteins (i.e., neoglycoproteins), and more recently
on glycan arrays [27, 169–172].
3.3 Glycan arrays
Glycan arrays, composed of a panel of oligosaccharides immobilized to a solid support to
which dilutions of GBPs are applied and their interaction subsequently quantified, provide a
powerful technology to characterize GBP specificity (reviewed in [173–180]). A major asset
of the array platform is the capability to rapidly interrogate GBP recognition with potentially
hundreds of structurally defined glycans simultaneously, offering rapid insight into
functional roles of fine structural features of glycans. Indeed, binding studies of members of
the galectin family assessed by glycan array demonstrated that galectins 1–3 have
differential specificity for sialylated glycans governed by fine structural features including
linkage, and these binding differences were reflected in cellular functional readouts of
galectin activity [181]. Furthermore, arrays containing structurally defined GAGs have been
developed, and studies with them have further supported the hypothesis that specific
sulfation and acetylation patterns on GAG sequences encode information for governing
interactions and, consequently, physiological function [82, 182–187].
Many GBPs achieve their specificity and affinity through multivalent interaction with
glycans. Capturing the physiological avidity of such interactions necessitates the appropriate
presentation of multiple GBPs (or multiple glycan-binding domains within a GBP) and
multiple glycan motifs. Oligosaccharide density, spacing, and orientation as well as linker
flexibility and length become key parameters towards optimizing array strategies to capture
biologically meaningful binding events [176]. Indeed, multiple studies have suggested that
particular formats of glycan presentation prevent binding events that have previously been
validated in other assays [175, 176, 188]. In one study, concanavalin A (a plant lectin)
showed equivalent binding to high- and low-affinity mannose oligosaccharides immobilized
at high density but demonstrated binding only to the high-affinity receptor at lower ligand
density [189]. As these studies suggest, it can be expected that there is no clear single set of
conditions that provides a universal optimum for all GBPs. Validation studies, such as
binding assays to obtain dissociation constants (e.g., surface plasmon resonance) and those
using physiologically relevant biological readouts (e.g., interaction with cells), are necessary
to confirm predictions made from glycan array analyses.
3.4 Integration across techniques
Integration of these techniques (functional genetics, glycan synthesis, and glycan arrays)
with analytical approaches is critical for a number of reasons (as summarized in recent
reviews [29, 30, 38, 44, 45, 133, 190–198]). In general, as described above, multiple glycan
sequences can bind to a given protein. Additional aspects, beyond sequence alone, govern
the specificity and biology of glycans, including multivalency, glycan topology, presence of
substituent groups, and other structural constraints. Moreover, while often genetic control of
a signaling pathway can often be understood in a binary way, as evidenced in the utility of
various gene manipulation techniques, glycan modulation of function is often more analog
in nature.
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Two case studies, one involving the binding of influenza A virus hemagglutinin (HA) to
sialylated receptors on the surface of airway epithelial cells and the other describing the
structural determination of a contaminant in heparin, highlight many of these concepts, and
provide specific examples where integration of approaches provided robust elucidation of
structure-function relationships.
4. Case studies
4.1 Receptor binding specificity of influenza virus
Influenza A virus interaction with sialylated glycan receptors has been studied for over five
decades and thus serves as a rich example to highlight an integrated strategy for defining
how fine structural features of sialylated glycans dictates interaction specificity, which in
turn governs a biological function, namely infection and pathogenesis. Influenza A viruses
exist commensally in wild aquatic bird populations without causing disease, thus making
birds the natural reservoir for influenza strains, though viruses may intermittently spread
through other species such as swine. As observed in the 1957, 1968, and the 2009 influenza
pandemics, genetic reassortments of avian-derived viruses can lead to adaptation of virus
such that they efficiently transmit between humans. Strains which demonstrate high human-
to-human transmissibility in addition to high virulence have increased risk to cause severe
disease outbreaks in people. Thus, one critical area with important scientific as well as
medical implications to address in this field is to define the molecular changes that govern
the shift from avian to human infectivity and transmissibility of influenza A viruses.
The infection process begins with attachment of viral HA to sialylated glycan receptors
located on host cells, and as such, the HA-glycan interaction is a critical step regulating
virus infectivity and selectivity. Biochemical studies of the HA-glycan interaction have
identified the presence of glycans with terminal sialic acid (Neu5Ac) linked α2→6 to
galactose (Neu5Ac α2→6 D-galactose [Gal], hereafter referred to as α2→6) to be a key
feature for human-adapted HA, whereas avian-adapted viruses have preference for terminal
sialic acid linked α2→3 to galactose (Neu5Acα2→3Gal, hereafter referred to as α2→3)
[199–203]. This biochemical characterization along with studies describing co-crystal
structures of HAs in complex with various glycan receptors [204–209] support the
hypothesis that for an influenza virus to cross over from avian to human-adapted, the
recognition specificity of its HA must switch preference from α2→3 glycans found on
avian tissues to α2→6 glycans. Although this hypothesis explained transmission specificity
for multiple viruses, cases were identified in which HAs representing different strains
exhibited mixed α2→3/α2→6 binding specificity but showed differential transmission in a
ferret animal model of human transmission, thereby confounding the correlation between
α2→6 glycan binding specificity and efficient human transmission [210]. These results
suggested HA binding preference defined by glycosidic linkage alone, namely α2→3 or
α2→6, is not a sufficient determinant to differentiate human- from avian-adapted HA.
To more fully explain the classification of avian- versus human-adapted HA in the context
of HA glycan binding specificity, application of additional tools was required to elucidate
finer structural properties of sialylated glycan receptors beyond the terminal Neu5Ac-
galactose glycosidic linkage. In a study by Chandrasekaran et al., multiple complementary
methodologies which both affirm and inform each other were employed to define fine
structural properties of sialylated glycan receptors and bridge these structures with
biophysical and biochemical binding features of HA, the results of which demonstrated a
specific glycan topology recognized by human- versus avian-adapted HA [211].
The upper respiratory tract serves as the primary target area for human-to-human
transmission of influenza A virus. In order to characterize potential target glycan receptors
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for influenza A virus, an analysis of the distribution and diversity of sialylated glycans found
on cell surfaces of upper airway tissues and cells was performed. Structures of
physiologically relevant sialylated glycan receptors were probed using the complementary
techniques of lectin staining and MALDI-MS [211]. A matrix of lectins was applied to stain
different tissue sections of upper respiratory tract, and glycan fine structure was analyzed
and quantified using MALDI-MS /MS coupled with pretreatments with sialidases having
different specificities. Incorporating complementary tools (i.e., lectins and glycosidases) to
MS aided the identification of a diversity of multiantennary sialylated glycans with the
presence of long oligosaccharide branches composed of multiple lactosamine repeats.
Structural information gathered from an MS-coupled approach informs the selection of
glycan targets for use in functional assays as well as guides interpretation of functional
readouts. Utilizing this strategy, a two-pronged methodology was employed to correlate
physiologically relevant glycan structures with HA binding preference [211]. First, data-
mining tools were applied to existing glycan array data of binding specificity of influenza A
virus and recombinant HA from various avian- and human-adapted strains. This informatics-
based approach identified patterns of structural features present (or absent) in glycan motifs
which demonstrated binding or non-binding in array experiments. Abstraction of binding
patterns led to rules indicating the importance of extension length on the non-reducing end
of sialic acid to classify α2→6 binders. Importantly, much of the existing glycan array data
was obtained from experiments utilizing only a single concentration of HA or titer of virus
in the binding assay. Interpretation of binding results using a single concentration is limited
and is generally framed in a binary “on” or “off” fashion [203, 212–214]. Such an analysis
necessarily obscures finer differences in specificity and affinity, particularly when saturating
concentrations are used.
To overcome these limitations as well as validate predictions generated by the data-mining
approach, a robust and quantitative binding assay was developed to measure HA and virus
specificity [215]. A panel of synthetic oligosaccharides was selected based on sialylated
glycan motifs identified in the coupled-MS approach as well as from predictions generated
by glycan array data mining. To accurately capture and compare specificity and affinity of
multivalent HA-glycan interactions across different HAs, two key variables were addressed.
First, to capture the avidity of HA-glycan interactions, recombinant HA was expressed as a
trimer with further multivalent presentation facilitated by precomplexation of trimeric HA
with primary and secondary antibodies, resulting in a locked spatial arrangement [215].
Such an approach fixed avidity effects across HA, thereby allowing for comparison of
binding affinity across HAs of different subtypes. The second variable was quantifying
relative binding affinity of HA to α2→3 and α2→6 linked glycan motifs. This was
accomplished by generating a binding isotherm across serial dilution of precomplexed HA
and calculation of an apparent dissociation constant (K’d) to capture the relative binding
affinities.
Designing binding assays that address these variables provided a framework to
quantitatively assess fine differences of binding specificity of HA from diverse strains.
Previous hypotheses were corroborated by demonstration that human-adapted HAs share
binding preference for α2→6 glycans containing multiple lactosamine (or lactose) repeats,
whereas avian-adapted HAs had high affinity for α2→3 glycans and α2→6 glycans
containing short extensions.
The above analyses provided a direct connection between structural analyses of
physiologically relevant sialylated glycan receptors from upper airways and the binding
specificity of avian- and human-adapted HA in the context of relevant glycan motifs. The
results suggested that, in addition to the glycosidic linkage between terminal sialic acid and
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penultimate galactose, the sugars extending beyond the penultimate galactose, and
particularly the length of the extension, play a role in binding differentiation of avian- versus
human-adapted HA. Molecular modeling analyses, utilizing existing co-crystal structures of
HA complexed with different glycan receptors, corroborated previous results and revealed
that a specific topology (termed umbrella-like topology) was adopted by α2→6 glycans
containing multiple lactosamine repeats [211]. In contrast, a distinct topology with a cone-
like shape was adopted by α2→3 and short α2→6 glycans. Cumulatively, these studies
illustrate an integrated approach for generating a direct and specific structural rationale for
binding specificity of avian-versus human-adapted HA (and viruses) to sialylated glycans,
which in turn correlates with airborne transmissibility of viruses (Figure 3).
The set of studies described here provides tangible insight into an integrated framework for
the structure-function study of acidic glycans. First, orthogonal techniques are typically
necessary to probe finer structural details beyond sequence, such as glycosidic linkage,
modifications, and conformation. This case study highlights the utility of coupling MS
analysis with lectin staining of tissue sections (distribution of physiologically relevant
glycans), glycosidase treatments (linkage), and molecular modeling (glycan conformation
and topology). Furthermore, this case study exemplifies how glycan sequence alone can be
insufficient to explain a glycan-mediated function, and that probing deeper simply by
additional layers of MS and MS/MS analysis may not necessarily reveal the key structural
determinants for a given activity. Indeed, the linking of structural results (MS-coupled
experiments) with functional results (glycan array studies) was critical to inform and guide
subsequent molecular analyses focused on structural and conformational aspects of extended
versus short sialylated terminal motifs.
The importance of informatics tools to decipher complex datasets is highlighted in this case
study. Several strains of HA (and virus) have been screened on glycan array platforms
comprising of hundreds of distinct glycan motifs. The size of this dataset overwhelms
manual interpretation methods, and thus informatics became a key tool to systematically
analyze the large dataset in an integrated manner so as to make all data comparable for
extracting useful information. Moreover, given that a multitude of related (or sometimes
unrelated) glycan motifs show binding signals on the array, it was necessary to develop
informatics tools to extract key glycan structural features shared by binders versus
nonbinders for a given HA.
4.2 Heparin contamination
Heparin is a mixture of highly sulfated GAG chains isolated from a biological source,
typically porcine intestinal mucosa, and is used clinically primarily as a prophylactic agent
to prevent thrombosis as well as an initial treatment of established venous thrombosis. These
heterogenous acidic polysaccharides are composed of 10–100 disaccharide repeat units of
N-acetyl/sulfo glucosamine (1→4) linked to hexuronic acid. In its simplest form, the
glucosamine (H) is N-acetylated and the uronic acid is β-D-glucuronic acid (G).
Modifications to this basic unit include N- and O-sulfonation (6-O and 3-O sulfo groups are
present in the glucosamine and 2-O sulfo groups in the uronic acid) as well as epimerization
of β-D-glucuronic acid (G) to α-L-iduronic acid (I) [216]. Heparin has enjoyed widespread
use as a medicinal agent; it and insulin are, on a unit basis, the most widely used
medications in the clinic. Heparin is standard therapy in a number of situations, such as
kidney dialysis and medical intervention of acute coronary events. In terms of worldwide
production, most of the crude, partially purified, heparin is produced in China; in addition,
China is a major locale for purification of heparin active pharmaceutical ingredient (API)
from crude heparin.
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Commercial heparins are derived from a number of sources, including porcine and bovine
intestine and lung mucosa, though heparin sold in the United States is almost exclusively
from porcine intestinal mucosa. Due to their biological source, as well as the employed
isolation procedure, heparin primarily contains highly sulfated chains, with ~60–90% of the
disaccharide units consisting of 2-O sulfo iduronic acid and 6-O sulfo, N-sulfo glucosamine
(abbreviated I2SHNS,6S). In a typical polysaccharide chain of heparin, repeats of this
trisulfated disaccharide unit are interrupted on occasion by other minor sequences, including
the antithrombin III binding pentasaccharide sequence, a key sequence for heparin’s
anticoagulant activity. On average, heparin consists of chains which contain 2.4–2.8 sulfates
per disaccharide; however, a combination of polydispersity, resulting in variable molecular
weight, as well as microheterogeneity, resulting in structural (sequence) variability between
chains, make heparin a complex pharmaceutical agent, one that orchestrates a range of
biological activities.
In late 2007 and early 2008, clusters of serious allergic-type events were reported in patients
undergoing hemodialysis who were receiving heparin. Efforts were made to identify the
source of these allergic-type reactions, and these initial investigations ruled out many
obvious causes, such as the presence of adventitious viral agents or the presence of greater
levels of protein impurities in suspect as compared to non-suspect lots of the drug [217].
Analysis of intact heparin by analytical techniques, such as CE and one-dimensional NMR,
demonstrated profile differences in suspect lots versus clean lots. However, while these
techniques could be used to screen the heparin supply and provide some indication of the
nature of the contamination, detailed structural work was complicated by the heparin’s
polydispersity and microheterogeneity to the point that structural elucidation of the
contaminant was not possible using strategies that had worked in the past to identify
structural signatures with heparin. Further complicating structural work was the fact that the
contaminant was refractory to digestion with heparinases, which, as described in section 3,
are often used to break heparin chains down into constituent parts for analysis [123, 218,
219].
Only through a combination of approaches was the contaminant ultimately identified as
oversulfated chondroitin sulfate (OSCS) [220, 221], a complex polysaccharide mixture
which had never before been observed in heparin (Figure 4A). In this case, to definitively
identify OSCS required the use of multiple analytical techniques including multidimensional
NMR, HPLC analysis, and MS. OSCS was found to have four sulfate groups per
disaccharide unit, which is rarely, if ever, found in nature and is structurally distinct from
other GAG impurities, such as dermatan sulfate. Consequently, it is unlikely that OSCS
arose from a natural source and was probably added, either accidentally or deliberately, to
heparin. Indeed, some suspect lots of heparin were found to contain approximately 30% of
contaminant [221]. The advent of OSCS contamination in heparin has led to the introduction
of new quality control tests, based on CE and NMR, which measure molecular level
attributes of heparin and that can readily detect OSCS contamination if present at levels
greater than 0.1–0.2%. However, OSCS is but one possible contaminant that could enter the
heparin supply, given that numerous persulfonated polysaccharides have global
anticoagulant activity.
Given heparin’s structural complexity as well as its use as a critical drug in the hospital, a
rigorous testing regimen will necessarily involve multiple tests. Such a testing strategy can
be thought of as a series of filters, where suspect heparin is captured by at least one of the
filters (i.e., fails testing specifications) and, accordingly, is removed from the supply chain.
Thus, the analytical testing regimen, or protocol, should be designed such that will be some
overlap in information content obtained from each test. Because of this overlap, through
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cross-correlation of results, it is possible to ensure the accuracy of testing results and
increase the overall confidence that a sample which passes is truly free of contamination.
Without this type of approach, there is a real risk of missing potential impurities/
contaminants within heparin. For example, with regards to a 1H NMR-based test, its
limitations should be expressly recognized. First, while this method can detect OSCS
containing approximately four sulfates per disaccharide, if the degree of sulfation for OSCS
is reduced, the prominent N-acetyl signal is lost behind that of heparin (Figure 4B). Another
issue at present is that the current 1H NMR test as practiced may not capture the presence of
other contaminants. For example, alginate sulfate, even at a level of 4%, is not detectable in
the proton NMR spectrum (Figure 4C).
The above situation is even more acute for CE/HPLC-based methods which analyze intact
heparin. CE/HPLC, which relies on absorbance at 210 nm, also cannot detect several
potential contaminants. Again, referring the above examples, any polysaccharide, including
alginate sulfate, which does not have appreciable absorbance at this wavelength would not
be detected. Furthermore, any contaminant with a sulfate (charge) density close to that of
heparin would migrate similarly to heparin and remain undetected. Clearly, there is the need
to develop alternative testing strategies that incorporate molecular-level information and
hence measure and account for heparin’s heterogeneity, thus resolving potential
contaminants.
Utilization and integration of the information provided by orthogonal methodologies avoids
these pitfalls encountered with a single technique. In this context, a method like 1H NMR is
not intended to capture every possible contaminant in heparin, and it is supplemented with
additional analytical technologies, such as enzymatic digestion and HPLC analysis, that
would detect contaminants invisible to NMR, including the aforementioned alginate sulfate.
5. Future of glycomics
Over the past several years, there has been a dramatic transformation in understanding the
structure and biology of complex glycans owing to development of synthesis, analytical and
informatics tools and technologies to study glycan structure-function relationships. These
developments have changed the notion of glycomics from a complex research field to an
area that is now readily accessible to a wide range of scientific disciplines including
analytical chemistry, biochemistry, structural biology, immunology, microbiology, cancer
research, computer science and informatics.
An important factor in opening up glycomics research to the broader scientific community is
the accelerated development of databases and computational and informatics tools to
acquire, integrate, annotate, mine and disseminate glycomics datasets such as analytical
data, glycan array data and glycogene expression data, etc. Much of the earlier efforts in
glycomics focused on structural characterization of glycans, development of glycan structure
databases and computational tools to assist assignment of glycan structures from high-
throughput analytical datasets. The development of these tools has advanced to a point
where it is possible to obtain robust and detailed profiling of a majority of glycans isolated
from cells, tissues and individual glycoproteins. As covered in this review, the acidic
glycans pose unique challenges in terms of structural characterization and efforts are
ongoing to improve the analytical tools for sensitive measurement of acidic glycans and
integrate information across multiple tools (facilitated by informatics) to address these
challenges.
An important future direction building on technologies to characterize glycan structure is to
bridge the space of the glycome with functional glycome. Advances in chemical and
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chemoenzymatic synthesis of glycans, neoglycoproteins and neoglycolipids that have led to
development of glycan array platforms, and functional readouts in terms of glycogene
expression and animal models have positioned the field to begin making this bridge.
However, unlike DNA and proteins where structural specificity can be readily translated into
sequence space, it is challenging to bridge the biophysical and biochemical specificity of
glycan-protein interactions with the biology.
A typical screening of a GBP on glycan array platforms gives several glycan sequence
motifs that show comparable high binding to that GBP. However, at the level of the three-
dimensional structural interactions, these diverse glycan sequence motifs adopt a distinct
shape or topology that optimally interacts with the GBP (Figure 5). For example, it has been
demonstrated that binding of a GAG chain to a protein induces a distinct kink in the three-
dimensional helical structure of GAG and the topological arrangement of sulfate groups to
make optimal contacts with the protein is governed by the nature and extent of the kink [83].
The importance of glycan shape and conformational constraints induced upon protein
binding has also been demonstrated for C-type lectins [188] and influenza A virus HA [211].
Therefore it is important to define specificity of glycan-protein interactions in context of
structural motif and possible set of sequence motifs that would satisfy the structural
constraints for optimal interaction with a GBP.
The aforementioned issues have motivated the development of computational tools for
determining binding motifs from glycan array data [211, 222] and for three-dimensional
modeling of glycan-protein interactions [223]. These computational tools will also facilitate
in guiding the expansion of functional glycome space by informing glycan synthesis
strategies to generate novel binding motifs that need to be explored in the context of
understanding biology governed by glycan-protein interactions.
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Abbreviations used
GAG glycosaminoglycan
HS heparan sulfate
CS chondroitin sulfate
DS dermatan sulfate
HPLC high performance liquid chromatography
MS mass spectrometry
CE capillary electrophoresis
NMR nuclear magnetic resonance
GBP glycan-binding protein
MALDI matrix-assisted laser desorption ionization
ESI electrospray ionization
GGDB GlycoGene DataBase
CAZy Carbohydrate-Active enZYme Database
Robinson et al. Page 14
Electrophoresis. Author manuscript; available in PMC 2013 August 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
KEGG Kyoto Encyclopedia for Genes and Genomes
CFG Consortium for Functional Glycomics
HA hemagglutinin
Neu5Ac N-Acetylneuraminic acid (sialic acid)
Gal galactose
SNA Sambucus nigra agglutinin
H glucosamine
G β-D-glucuronic acid
I α-L-iduronic acid
API active pharmaceutical ingredient
OSCS oversulfated chondroitin sulfate
ds degree of sulfation
FGF fibroblast growth factor
References
1. Varki, A. Essentials of glycobiology. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory
Press; 2009.
2. Lowe JB, Marth JD. Annu Rev Biochem. 2003; 72:643–691. [PubMed: 12676797]
3. Tabak LA. Semin Cell Dev Biol. 2010; 21:616–621. [PubMed: 20144722]
4. Haltiwanger RS, Lowe JB. Annu Rev Biochem. 2004; 73:491–537. [PubMed: 15189151]
5. Hwang HY, Olson SK, Esko JD, Horvitz HR. Nature. 2003; 423:439–443. [PubMed: 12761549]
6. Marth JD, Grewal PK. Nat Rev Immunol. 2008; 8:874–887. [PubMed: 18846099]
7. Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. Science. 2001; 291:2370–2376. [PubMed:
11269318]
8. van Kooyk Y, Rabinovich GA. Nat Immunol. 2008; 9:593–601. [PubMed: 18490910]
9. Haines N, Irvine KD. Nat Rev Mol Cell Biol. 2003; 4:786–797. [PubMed: 14570055]
10. Varki A. Nature. 2007; 446:1023–1029. [PubMed: 17460663]
11. Ohtsubo K, Marth JD. Cell. 2006; 126:855–867. [PubMed: 16959566]
12. Fuster MM, Esko JD. Nat Rev Cancer. 2005; 5:526–542. [PubMed: 16069816]
13. Lau KS, Dennis JW. Glycobiology. 2008; 18:750–760. [PubMed: 18701722]
14. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz
M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, Ashkenazi A. Nat Med.
2007; 13:1070–1077. [PubMed: 17767167]
15. Liu FT, Rabinovich GA. Nat Rev Cancer. 2005; 5:29–41. [PubMed: 15630413]
16. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Nat Rev Cancer. 2002; 2:521–528.
[PubMed: 12094238]
17. Dube DH, Bertozzi CR. Nat Rev Drug Discov. 2005; 4:477–488. [PubMed: 15931257]
18. Nilsson EC, Storm RJ, Bauer J, Johansson SM, Lookene A, Angstrom J, Hedenstrom M, Eriksson
TL, Frangsmyr L, Rinaldi S, Willison HJ, Domellof FP, Stehle T, Arnberg N. Nat Med. 2011;
17:105–109. [PubMed: 21151139]
19. Scanlan CN, Offer J, Zitzmann N, Dwek RA. Nature. 2007; 446:1038–1045. [PubMed: 17460665]
20. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. Nat Med. 1997;
3:866–871. [PubMed: 9256277]
21. Helenius A, Aebi M. Science. 2001; 291:2364–2369. [PubMed: 11269317]
Robinson et al. Page 15
Electrophoresis. Author manuscript; available in PMC 2013 August 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
22. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Journal of the American
Society of Nephrology. 1999; 10:2392–2395. [PubMed: 10541299]
23. Mattio M, Ceaglio N, Oggero M, Perotti N, Amadeo I, Orozco G, Forno G, Kratje R,
Etcheverrigaray M. Biotechnology Progress. 2011; 27:1018–1028. [PubMed: 21608141]
24. Sasisekharan R, Raman R, Prabhakar V. Annu Rev Biomed Eng. 2006; 8:181–231. [PubMed:
16834555]
25. Schnaar, RL.; Suzuki, A.; Stanley, P. Essentials of Glycobiology. Varki, A.; Cummings, R.; Esko,
JD.; Freeze, HH.; Stanley, P.; Bertozzi, CR.; Hart, GW.; Etzler, ME., editors. Cold Spring Harbor:
Cold Spring Harbor Laboratory Press; 2009.
26. Taylor, ME.; Drickamer, K. Introduction to glycobiology. New York: Oxford University Press,
Oxford; 2003.
27. Collins BE, Paulson JC. Curr Opin Chem Biol. 2004; 8:617–625. [PubMed: 15556405]
28. Kiessling, LL.; Young, T.; Gruber, TD.; Mortell, KH. Fraser-Reid, BO.; Tatsuta, K.; Thiem, J.,
editors. Springer Berlin Heidelberg; 2008. p. 2483-2523.
29. Marino K, Bones J, Kattla JJ, Rudd PM. Nat Chem Biol. 2010; 6:713–723. [PubMed: 20852609]
30. Vanderschaeghe D, Festjens N, Delanghe J, Callewaert N. Biological Chemistry. 2010; 391:149–
161. [PubMed: 20128687]
31. Zaia J. OMICS. 2010; 14:401–418. [PubMed: 20443730]
32. Kato, K.; Yamaguchi, Y. Experimental Glycoscience. Taniguchi, N.; Suzuki, A.; Ito, Y.;
Narimatsu, H.; Kawasaki, T.; Hase, S., editors. Springer Japan; 2008. p. 45-50.
33. Cummings, RD. Lectins as Tools for Glycoconjugate Purification and Characterization. Wiley-
VCH Verlag GmbH; 2008.
34. El Rassi, Z., editor. Carbohydrate analysis by modern chromatography and electrophoresis.
Elsevier; 2002.
35. Nakano, M.; Kakehi, K.; Taniguchi, N.; Kondo, A. Volpi, N., editor. Humana Press; 2011. p.
205-235.
36. Mechref Y, Novotny MV. Mass Spectrom Rev. 2009; 28:207–222. [PubMed: 18973241]
37. Pilobello KT, Mahal LK. Curr Opin Chem Biol. 2007; 11:300–305. [PubMed: 17500024]
38. Mechref Y, Novotny MV. Chem Rev. 2002; 102:321–369. [PubMed: 11841246]
39. Seeberger, PH.; Finney, N.; Rabuka, D.; Bertozzi, CR. Essentials of glycobiology. Varki, A.;
Cummings, RD.; Esko, JD.; Freeze, HH.; Stanley, P.; Bertozzi, CR.; Hart, GW.; Etzler, ME.,
editors. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2009.
40. Blixt O, Razi N. Methods Enzymol. 2006; 415:137–153. [PubMed: 17116472]
41. Bertozzi CR, Kiessling LL. Science. 2001; 291:2357–2364. [PubMed: 11269316]
42. Bernardes, Ga. J. L; Castagner, B.; Seeberger, PH. ACS Chemical Biology. 2009; 4:703–713.
[PubMed: 19271728]
43. Seeberger PH, Werz DB. Nature. 2007; 446:1046–1051. [PubMed: 17460666]
44. Paulson JC, Blixt O, Collins BE. Nat Chem Biol. 2006; 2:238–248. [PubMed: 16619023]
45. Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R. Nat Methods. 2005; 2:817–
824. [PubMed: 16278650]
46. Honke, K.; Taniguchi, N. The sugar code. Fundamentals of glycosciences. Gabius, HJ., editor.
Weinheim: Wiley-VCH; 2009. p. 385-401.
47. von der Lieth, C-W. Bioinformatics for Glycobiology and Glycomics. John Wiley & Sons, Ltd;
2009. p. 1-20.
48. Ceroni, A.; Joshi, HJ.; Maaß, K.; Ranzinger, R.; Lieth, C-W. von d Glycoscience. Fraser-Reid,
BO.; Tatsuta, K.; Thiem, J., editors. Springer Berlin Heidelberg; 2008. p. 2219-2240.
49. Perez S, Mulloy B. Curr Opin Struct Biol. 2005; 15:517–524. [PubMed: 16143513]
50. Raman, R.; Sasisekharan, R. Wiley Encyclopedia of Chemical Biology. Begley, TP., editor.
Hoboken, New Jersey: John Wiley & Sons, Inc.; 2007.
51. Bocker S, Kehr B, Rasche F. IEEE/ACM Trans Comput Biol Bioinform. 2010
52. Harvey DJ. International Journal of Mass Spectrometry. 2003; 226:1–35.
53. Harvey DJ. Expert Rev Proteomics. 2005; 2:87–101. [PubMed: 15966855]
Robinson et al. Page 16
Electrophoresis. Author manuscript; available in PMC 2013 August 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
54. Liu X, McNally DJ, Nothaft H, Szymanski CM, Brisson JR, Li J. Anal Chem. 2006; 78:6081–
6087. [PubMed: 16944887]
55. Mechref Y, Novotny MV, Krishnan C. Anal Chem. 2003; 75:4895–4903. [PubMed: 14674469]
56. Morelle W, Michalski JC. Curr Pharm Des. 2005; 11:2615–2645. [PubMed: 16101462]
57. Zaia J. Chem Biol. 2008; 15:881–892. [PubMed: 18804025]
58. Haslam SM, North SJ, Dell A. Curr Opin Struct Biol. 2006; 16:584–591. [PubMed: 16938453]
59. Brisson JR, Vinogradov E, McNally DJ, Khieu NH, Schoenhofen IC, Logan SM, Jarrell H.
Methods Mol Biol. 2010; 600:155–173. [PubMed: 19882127]
60. Duus J, Gotfredsen CH, Bock K. Chem Rev. 2000; 100:4589–4614. [PubMed: 11749359]
61. Leeflang BR, Faber EJ, Erbel P, Vliegenthart JF. J Biotechnol. 2000; 77:115–122. [PubMed:
10674218]
62. Vliegenthart Johannes, FG. NMR Spectroscopy and Computer Modeling of Carbohydrates.
American Chemical Society; 2006. p. 1-19.
63. von der Lieth, C-W. NMR Databases and Tools for Automatic Interpretation of Spectra of
Carbohydrates. John Wiley & Sons, Ltd; 2009.
64. Cummings, RD. Methods in Enzymology. William, J.; Lennarz, GWH., editors. Academic Press;
1994. p. 66-86.
65. Endo, T. Journal of Chromatography Library. El Ziad, R., editor. Elsevier; 2002. p. 251-265.
66. Hirabayashi J. Glycoconj J. 2004; 21:35–40. [PubMed: 15467396]
67. Gupta G, Surolia A, Sampathkumar SG. OMICS. 2010; 14:419–436. [PubMed: 20726799]
68. Hsu KL, Mahal LK. Curr Opin Chem Biol. 2009; 13:427–432. [PubMed: 19716334]
69. Krishnamoorthy, L.; Mahal, LK. Functional and Structural Proteomics of Glycoproteins. Owens,
R.; Nettleship, J., editors. Springer Netherlands; 2011. p. 91-102.
70. Rüdiger H, Gabius H-J. Glycoconjugate Journal. 2001; 18:589–613. [PubMed: 12376725]
71. Tao SC, Li Y, Zhou J, Qian J, Schnaar RL, Zhang Y, Goldstein IJ, Zhu H, Schneck JP.
Glycobiology. 2008; 18:761–769. [PubMed: 18625848]
72. Wu A, Lisowska E, Duk M, Yang Z. Glycoconjugate Journal. 2009; 26:899–913. [PubMed:
18368479]
73. Hirabayashi J. Journal of Biochemistry. 2008; 144:139–147. [PubMed: 18390573]
74. Lowe, JB.; Marth, JD. Essentials of Glycobiology. Varki, A., editor. Cold Spring Harbor: Cold
Spring Harbor Laboratory Press; 1999. p. 211-252.
75. Gagneux P, Varki A. Glycobiology. 1999; 9:747–755. [PubMed: 10406840]
76. Stick, RV.; Williams, SJ. Carbohydrates: the essential molecules of life. Stick, RV.; Williams, SJ.,
editors. Amsterdam: Elsevier Science; 2008. p. 364-367.
77. Chen X, Varki A. ACS Chem Biol. 2010; 5:163–176. [PubMed: 20020717]
78. Schauer R. Curr Opin Struct Biol. 2009; 19:507–514. [PubMed: 19699080]
79. Varki A. Trends Mol Med. 2008; 14:351–360. [PubMed: 18606570]
80. Cohen M, Varki A. OMICS. 2010; 14:455–464. [PubMed: 20726801]
81. Gama CI, Hsieh-Wilson LC. Current Opinion in Chemical Biology. 2005; 9:609–619. [PubMed:
16242378]
82. Gama CI, Tully SE, Sotogaku N, Clark PM, Rawat M, Vaidehi N, Goddard WA, Nishi A, Hsieh-
Wilson LC. Nat Chem Biol. 2006; 2:467–473. [PubMed: 16878128]
83. Raman R, Sasisekharan V, Sasisekharan R. Chemistry & Biology. 2005; 12:267–277. [PubMed:
15797210]
84. Lamanna WC, Kalus I, Padva M, Baldwin RJ, Merry CLR, Dierks T. Journal of Biotechnology.
2007; 129:290–307. [PubMed: 17337080]
85. Lamari F, Militsopoulou M, Gioldassi X, Karamanos N. Fresenius' Journal of Analytical
Chemistry. 2001; 371:157–167. [PubMed: 11678186]
86. Ruhaak L, Zauner G, Huhn C, Bruggink C, Deelder A, Wuhrer M. Analytical and Bioanalytical
Chemistry. 2010; 397:3457–3481. [PubMed: 20225063]
87. Harvey DJ. Mass Spectrometry Reviews. 1999; 18:349–450. [PubMed: 10639030]
Robinson et al. Page 17
Electrophoresis. Author manuscript; available in PMC 2013 August 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
88. Talbo G, Mann M. Rapid Communications in Mass Spectrometry. 1996; 10:100–103. [PubMed:
8563011]
89. Zaia J. Mass Spectrometry Reviews. 2004; 23:161–227. [PubMed: 14966796]
90. Powell AK, Harvey DJ. Rapid Communications in Mass Spectrometry. 1996; 10:1027–1032.
[PubMed: 8755235]
91. An HJ, Lebrilla CB. Israel Journal of Chemistry. 2001; 41:117–128.
92. Fukuyama Y, Nakaya S, Yamazaki Y, Tanaka K. Analytical Chemistry. 2008; 80:2171–2179.
[PubMed: 18275166]
93. Laremore TN, Murugesan S, Park T-J, Avci FY, Zagorevski DV, Linhardt RJ. Analytical
Chemistry. 2006; 78:1774–1779. [PubMed: 16536411]
94. Papac DI, Wong A, Jones AJS. Analytical Chemistry. 1996; 68:3215–3223. [PubMed: 8797382]
95. Pitt JJ, Gorman JJ. Rapid Communications in Mass Spectrometry. 1996; 10:1786–1788.
96. Zhang J, LaMotte L, Dodds ED, Lebrilla CB. Analytical Chemistry. 2005; 77:4429–4438.
[PubMed: 16013856]
97. Juhasz P, Biemann K. Proceedings of the National Academy of Sciences. 1994; 91:4333–4337.
98. Mechref Y, Novotny MV. Journal of the American Society for Mass Spectrometry. 1998; 9:1293–
1302. [PubMed: 9835074]
99. Jacobs A, Dahlman O. Analytical Chemistry. 2000; 73:405–410. [PubMed: 11217739]
100. Harvey DJ. J Chromatogr B Analyt Technol Biomed Life Sci. 2010
101. Wada Y, Azadi P, Costello CE, Dell A, Dwek RA, Geyer H, Geyer R, Kakehi K, Karlsson NG,
Kato K, Kawasaki N, Khoo K-H, Kim S, Kondo A, Lattova E, Mechref Y, Miyoshi E, Nakamura
K, Narimatsu H, Novotny MV, Packer NH, Perreault H, Peter-Katalinić J, Pohlentz G, Reinhold
VN, Rudd PM, Suzuki A, Taniguchi N. Glycobiology. 2007; 17:411–422. [PubMed: 17223647]
102. Ciucanu I, Kerek F. Carbohydrate Research. 1984; 131:209–217.
103. Ciucanu I. Analytica Chimica Acta. 2006; 576:147–155. [PubMed: 17723627]
104. Dell, A.; Reason, AJ.; Khoo, K-H.; Panico, M.; McDowell, RA.; Morris, HR. Methods in
Enzymology. William, J.; Lennarz, GWH., editors. Academic Press; 1994. p. 108-132.
105. Sekiya S, Wada Y, Tanaka K. Analytical Chemistry. 2005; 77:4962–4968. [PubMed: 16053310]
106. Lei M, Mechref Y, Novotny MV. Journal of the American Society for Mass Spectrometry. 2009;
20:1660–1671. [PubMed: 19546010]
107. Thomsson KA, Karlsson NG, Hansson GC. Journal of Chromatography A. 1999; 854:131–139.
[PubMed: 10497934]
108. Hitchcock AM, Costello CE, Zaia J. Biochemistry. 2006; 45:2350–2361. [PubMed: 16475824]
109. Thomsson KA, Schulz BL, Packer NH, Karlsson NG. Glycobiology. 2005; 15:791–804.
[PubMed: 15814823]
110. Robbe C, Capon C, Coddeville B, Michalski J-C. Rapid Communications in Mass Spectrometry.
2004; 18:412–420. [PubMed: 14966848]
111. Manzi AE, Norgard-Sumnicht K, Argade S, Marth JD, van Halbeek H, Varki A. Glycobiology.
2000; 10:669–689. [PubMed: 10910972]
112. Lütteke T, Bohne-Lang A, Loss A, Goetz T, Frank M, von der Lieth C-W. Glycobiology. 2006;
16:71R–81R.
113. Lundborg M, Widmalm G. Anal Chem. 2011
114. Jansson P-E, Stenutz R, Widmalm G. Carbohydrate Research. 2006; 341:1003–1010. [PubMed:
16564037]
115. Lütteke T. ChemBioChem. 2008; 9:2155–2160. [PubMed: 18693281]
116. Royle L, Mattu TS, Hart E, Langridge JI, Merry AH, Murphy N, Harvey DJ, Dwek RA, Rudd
PM. Anal Biochem. 2002; 304:70–90. [PubMed: 11969191]
117. Rudd PM, Colominas C, Royle L, Murphy N, Hart E, Merry AH, Hebestreit HF, Dwek RA.
Proteomics. 2001; 1:285–294. [PubMed: 11680875]
118. Campbell MP, Royle L, Radcliffe CM, Dwek RA, Rudd PM. Bioinformatics. 2008; 24:1214–
1216. [PubMed: 18344517]
Robinson et al. Page 18
Electrophoresis. Author manuscript; available in PMC 2013 August 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
119. Zhao J, Simeone DM, Heidt D, Anderson MA, Lubman DM. Journal of Proteome Research.
2006; 5:1792–1802. [PubMed: 16823988]
120. Stadlmann J, Weber A, Pabst M, Anderle H, Kunert RJ, Ehrlich H, Peter Schwarz H, Altmann F.
Proteomics. 2009; 9:4143–4153. [PubMed: 19688751]
121. McDonald CA, Yang JY, Marathe V, Yen T-Y, Macher BA. Molecular & Cellular Proteomics.
2009; 8:287–301. [PubMed: 18923192]
122. Guerrini M, Raman R, Venkataraman G, Torri G, Sasisekharan R, Casu B. Glycobiology. 2002;
12:713–719. [PubMed: 12460939]
123. Venkataraman G, Shriver Z, Raman R, Sasisekharan R. Science. 1999; 286:537–542. [PubMed:
10521350]
124. Hirabayashi J, Kuno A, Tateno H. Electrophoresis. 2011; 32:1118–1128. [PubMed: 21544837]
125. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Nature. 2006; 440:435–436.
[PubMed: 16554799]
126. Nicholls J, Bourne A, Chen H, Guan Y, Peiris JM. Respiratory Research. 2007; 8:73. [PubMed:
17961210]
127. Brooks SA, Hall DMS, Buley I. Br J Cancer. 2001; 85:1014–1022. [PubMed: 11592774]
128. Danguy A, Decaestecker C, Genten F, Salmon I, Kiss R. Cells Tissues Organs. 1998; 161:206–
218.
129. Caron, M.; Seve, A-P., editors. Lectins and Pathology. Amsterdam: Harwood Academic
Publishers; 2000.
130. Varki NM, Varki A. Lab Invest. 2007; 87:851–857. [PubMed: 17632542]
131. Raman, R.; Sasisekharan, R.; Begley, TP. Wiley Encyclopedia of Chemical Biology. John Wiley
& Sons, Inc; 2007.
132. von der Lieth CW, Lutteke T, Frank M. Biochim Biophys Acta. 2006; 1760:568–577. [PubMed:
16459020]
133. von der Lieth, CW. Bioinformatics for Glycobiology and Glycomics: An Introduction. Von der
Lieth, CW.; Lutteke, T.; Frank, M., editors. Chichester: John Wiley & Sons Ltd; 2009. p.
195-202.
134. Von der Lieth, CW. Comprehensive Glycoscience. Johannis, PK., editor. Oxford: Elsevier; 2007.
p. 329-346.Editor-in-Chief
135. Aoki-Kinoshita KF. PLoS Comput Biol. 2008; 4:e1000075. [PubMed: 18516240]
136. Ranzinger, R.; Maaß, K.; Lütteke, T. Owens, R.; Nettleship, J., editors. Springer Netherlands;
2011. p. 59-90.
137. von der Lieth C-W, Freire AA, Blank D, Campbell MP, Ceroni A, Damerell DR, Dell A, Dwek
RA, Ernst B, Fogh R, Frank M, Geyer H, Geyer R, Harrison MJ, Henrick K, Herget S, Hull WE,
Ionides J, Joshi HJ, Kamerling JP, Leeflang BR, Lütteke T, Lundborg M, Maass K, Merry A,
Ranzinger R, Rosen J, Royle L, Rudd PM, Schloissnig S, Stenutz R, Vranken WF, Widmalm G,
Haslam SM. Glycobiology. 2011; 21:493–502. [PubMed: 21106561]
138. Cooper CA, Gasteiger E, Packer NH. Proteomics. 2001; 1:340–349. [PubMed: 11680880]
139. Goldberg D, Sutton-Smith M, Paulson J, Dell A. Proteomics. 2005; 5:865–875. [PubMed:
15693066]
140. Packer NH, von der Lieth CW, Aoki-Kinoshita KF, Lebrilla CB, Paulson JC, Raman R, Rudd P,
Sasisekharan R, Taniguchi N, York WS. Proteomics. 2008; 8:8–20. [PubMed: 18095367]
141. Lohmann KK, von der Lieth C-W. Nucleic Acids Research. 2004; 32:W261–W266. [PubMed:
15215392]
142. Ceroni A, Maass K, Geyer H, Geyer R, Dell A, Haslam SM. J Proteome Res. 2008; 7:1650–1659.
[PubMed: 18311910]
143. Ceroni A, Dell A, Haslam S. Source Code for Biology and Medicine. 2007; 2:3. [PubMed:
17683623]
144. Tang H, Mechref Y, Novotny MV. Bioinformatics. 2005; 21(Suppl 1):431–i439.
145. Zhang H, Singh S, Reinhold VN. Anal Chem. 2005; 77:6263–6270. [PubMed: 16194087]
Robinson et al. Page 19
Electrophoresis. Author manuscript; available in PMC 2013 August 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
146. Gaucher SP, Morrow J, Leary JA. Analytical Chemistry. 2000; 72:2331–2336. [PubMed:
10857602]
147. Ethier M, Saba JA, Ens W, Standing KG, Perreault H. Rapid Commun Mass Spectrom. 2002;
16:1743–1754. [PubMed: 12207362]
148. Lapadula AJ, Hatcher PJ, Hanneman AJ, Ashline DJ, Zhang H, Reinhold VN. Anal Chem. 2005;
77:6271–6279. [PubMed: 16194088]
149. Nairn, A.; Moremen, K. Handbook of glycomics. Cummings, R., editor. London: Elsevier; 2009.
p. 95-136.
150. Comelli EM, Amado M, Head SR, Paulson JC. Biochem Soc Symp. 2002:135–142. [PubMed:
12655780]
151. Comelli EM, Head SR, Gilmartin T, Whisenant T, Haslam SM, North SJ, Wong NK, Kudo T,
Narimatsu H, Esko JD, Drickamer K, Dell A, Paulson JC. Glycobiology. 2006; 16:117–131.
[PubMed: 16237199]
152. Nairn AV, York WS, Harris K, Hall EM, Pierce JM, Moremen KW. J Biol Chem. 2008;
283:17298–17313. [PubMed: 18411279]
153. Bishop JR, Schuksz M, Esko JD. Nature. 2007; 446:1030–1037. [PubMed: 17460664]
154. Forsberg E, Kjellén L. The Journal of Clinical Investigation. 2001; 108:175–180. [PubMed:
11457868]
155. Perrimon N, Bernfield M. Nature. 2000; 404:725–728. [PubMed: 10783877]
156. Inatani M, Irie F, Plump AS, Tessier-Lavigne M, Yamaguchi Y. Science. 2003; 302:1044–1046.
[PubMed: 14605369]
157. Schwarzkopf M, Knobeloch K-P, Rohde E, Hinderlich S, Wiechens N, Lucka L, Horak I, Reutter
W, Horstkorte R. Proceedings of the National Academy of Sciences. 2002; 99:5267–5270.
158. Galeano B, Klootwijk R, Manoli I, Sun M, Ciccone C, Darvish D, Starost MF, Zerfas PM,
Hoffmann VJ, Hoogstraten-Miller S, Krasnewich DM, Gahl WA, Huizing M. The Journal of
Clinical Investigation. 2007; 117:1585–1594. [PubMed: 17549255]
159. Lepenies B, Yin J, Seeberger PH. Curr Opin Chem Biol. 2010; 14:404–411. [PubMed: 20227905]
160. Park S, Lee M-R, Shin I. Chemical Society Reviews. 2008; 37:1579–1591. [PubMed: 18648683]
161. Muthana S, Cao H, Chen X. Curr Opin Chem Biol. 2009; 13:573–581. [PubMed: 19833544]
162. Chen J, Jones CL, Liu J. Chemistry &amp; Biology. 2007; 14:986–993. [PubMed: 17884631]
163. Linhardt RJ, Dordick JS, Deangelis PL, Liu J. Semin Thromb Hemost. 2007; 33453:465.
164. Avci Fikri, Y.; DeAngelis Paul, L.; Liu, J.; Linhardt Robert, J. Frontiers in Modern Carbohydrate
Chemistry. American Chemical Society; 2007. p. 253-284.
165. Liu R, Xu Y, Chen M, Weïwer M, Zhou X, Bridges AS, DeAngelis PL, Zhang Q, Linhardt RJ,
Liu J. Journal of Biological Chemistry. 2010; 285:34240–34249. [PubMed: 20729556]
166. Kiefel MJ, von Itzstein M. Chemical Reviews. 2002; 102:471–490. [PubMed: 11841251]
167. Blixt O, Allin K, Pereira L, Datta A, Paulson JC. Journal of the American Chemical Society.
2002; 124:5739–5746. [PubMed: 12010048]
168. Chokhawala HA, Huang S, Lau K, Yu H, Cheng J, Thon V, Hurtado-Ziola N, Guerrero JA, Varki
A, Chen X. ACS Chemical Biology. 2008; 3:567–576. [PubMed: 18729452]
169. Kiessling LL, Splain RA. Annual Review of Biochemistry. 2010; 79:619–653.
170. Kiessling LL, Gestwicki JE, Strong LE. Angewandte Chemie International Edition. 2006;
45:2348–2368.
171. Pieters RJ. Organic & Biomolecular Chemistry. 2009; 7:2013–2025. [PubMed: 19421435]
172. Lundquist JJ, Toone EJ. Chemical Reviews. 2002; 102:555–578. [PubMed: 11841254]
173. Smith, DF.; Cummings, RD. Handbook of glycomics. Cummings, RD.; Pierce, JM., editors.
Amsterdam: Elsevier; 2009. p. 139-160.
174. Smith, DF.; Song, X.; Cummings, RD. Methods in Enzymology. Minoru, F., editor. Academic
Press; 2010. p. 417-444.
175. Rillahan, CD.; Paulson, JC. Annual Review of Biochemistry. Vol. 80. null; 2011.
176. Oyelaran O, Gildersleeve JC. Current Opinion in Chemical Biology. 2009; 13:406–413.
[PubMed: 19625207]
Robinson et al. Page 20
Electrophoresis. Author manuscript; available in PMC 2013 August 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
177. Horlacher T, Seeberger PH. Chemical Society Reviews. 2008; 37:1414–1422. [PubMed:
18568167]
178. Lonardi E, Balog CI, Deelder AM, Wuhrer M. Expert Rev Proteomics. 2010; 7:761–774.
[PubMed: 20973647]
179. Liu Y, Palma AS, Feizi T. Biological Chemistry. 2009; 390:647–656. [PubMed: 19426131]
180. Liang P-H, Wu C-Y, Greenberg WA, Wong C-H. Current Opinion in Chemical Biology. 2008;
12:86–92. [PubMed: 18258211]
181. Stowell SR, Arthur CM, Mehta P, Slanina KA, Blixt O, Leffler H, Smith DF, Cummings RD.
Journal of Biological Chemistry. 2008; 283:10109–10123. [PubMed: 18216021]
182. Tully SE, Rawat M, Hsieh-Wilson LC. Journal of the American Chemical Society. 2006;
128:7740–7741. [PubMed: 16771479]
183. Shipp EL, Hsieh-Wilson LC. Chemistry & Biology. 2007; 14:195–208. [PubMed: 17317573]
184. de Paz JL, Moseman EA, Noti C, Polito L, von Andrian UH, Seeberger PH. ACS Chemical
Biology. 2007; 2:735–744. [PubMed: 18030990]
185. Rogers CJ, Clark PM, Tully SE, Abrol R, Garcia KC, Goddard WA, Hsieh-Wilson LC.
Proceedings of the National Academy of Sciences. 2011; 108:9747–9752.
186. de Paz JL, Seeberger PH. Molecular BioSystems. 2008; 4:707–711. [PubMed: 18563243]
187. Noti C, de Paz JL, Polito L, Seeberger PH. Chemistry – A European Journal. 2006; 12:8664–
8686.
188. Taylor ME, Drickamer K. Glycobiology. 2009; 19:1155–1162. [PubMed: 19528664]
189. Zhang Y, Li Q, Rodriguez LG, Gildersleeve JC. Journal of the American Chemical Society. 2010;
132:9653–9662. [PubMed: 20583754]
190. York, WS.; Kochut, KJ.; Miller, JA. Handbook of Glycomics. Richard, DC.; Pierce, JM., editors.
San Diego: Academic Press; 2010. p. 177-195.
191. Turnbull JE, Linhardt RJ. Nat Chem Biol. 2006; 2:449–450. [PubMed: 16921352]
192. Visvanathan M, Siddam SR, Lee IH, Lushington GH, Bousfield GR. Open Med Inform J. 2011;
5:9–16. [PubMed: 21603090]
193. Bertozzi, CR.; Sasisekharan, R. Essentials of Glycobiology. Varki, A.; Cummings, R.; Esko, JD.;
Freeze, HH.; Stanley, P.; Bertozzi, CR.; Hart, GW.; Etzler, ME., editors. Cold Spring Harbor:
Cold Spring Harbor Laboratory Press; 2009.
194. Turnbull JE, Field RA. Nat Chem Biol. 2007; 3:74–77. [PubMed: 17235338]
195. Prescher JA, Bertozzi CR. Cell. 2006; 126:851–854. [PubMed: 16959565]
196. Turnbull JE, Sasisekharan R. OMICS: A Journal of Integrative Biology. 2010; 14:385–387.
[PubMed: 20726798]
197. Hart GW, Copeland RJ. Cell. 2010; 143:672–676. [PubMed: 21111227]
198. Li J, Richards JC. 2009:1–8.
199. Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, Brown EG, Holtzman MJ, Brody SL. J.
Virol. 2006; 80:7469–7480. [PubMed: 16840327]
200. Russell R, Stevens D, Haire L, Gamblin S, Skehel J. Glycoconjugate Journal. 2006; 23:85–92.
[PubMed: 16575525]
201. Skehel JJ, Wiley DC. Annual Review of Biochemistry. 2000; 69:531–569.
202. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RAM, Osterhaus ADME, Kuiken
T. The American Journal of Pathology. 2007; 171:1215–1223. [PubMed: 17717141]
203. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. Science. 2006;
312:404–410. [PubMed: 16543414]
204. Eisen MB, Sabesan S, Skehel JJ, Wiley DC. Virology. 1997; 232:19–31. [PubMed: 9185585]
205. Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, Ha Y, Vasisht N, Steinhauer DA, Daniels
RS, Elliot A, Wiley DC, Skehel JJ. Science. 2004; 303:1838–1842. [PubMed: 14764886]
206. Ha Y, Stevens DJ, Skehel JJ, Wiley DC. Proceedings of the National Academy of Sciences. 2001;
98:11181–11186.
207. Ha Y, Stevens DJ, Skehel JJ, Wiley DC. Virology. 2003; 309:209–218. [PubMed: 12758169]
Robinson et al. Page 21
Electrophoresis. Author manuscript; available in PMC 2013 August 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
208. Sauter NK, Hanson JE, Glick GD, Brown JH, Crowther RL, Park SJ, Skehel JJ, Wiley DC.
Biochemistry. 1992; 31:9609–9621. [PubMed: 1327122]
209. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. Nature. 1988; 333:426–431.
[PubMed: 3374584]
210. Tumpey TM, Maines TR, Van Hoeven N, Glaser L, Solórzano A, Pappas C, Cox NJ, Swayne DE,
Palese P, Katz JM, García-Sastre A. Science. 2007; 315:655–659. [PubMed: 17272724]
211. Chandrasekaran A, Srinivasan A, Raman R, Viswanathan K, Raguram S, Tumpey TM,
Sasisekharan V, Sasisekharan R. Nat Biotechnol. 2008; 26:107–113. [PubMed: 18176555]
212. Coombs PJ, Taylor ME, Drickamer K. Glycobiology. 2006; 16:1C–7C. [PubMed: 16118287]
213. Stevens J, Blixt O, Paulson JC, Wilson IA. Nat Rev Micro. 2006; 4:857–864.
214. Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, Paulson JC, Wilson IA. Journal of
Molecular Biology. 2006; 355:1143–1155. [PubMed: 16343533]
215. Srinivasan A, Viswanathan K, Raman R, Chandrasekaran A, Raguram S, Tumpey TM,
Sasisekharan V, Sasisekharan R. Proceedings of the National Academy of Sciences. 2008;
105:2800–2805.
216. Sasisekharan R, Venkataraman G. Current Opinion in Chemical Biology. 2000; 4:626–631.
[PubMed: 11102866]
217. Sasisekharan R, Shriver Z. Thromb Haemost. 2009; 102:854–858. [PubMed: 19888519]
218. Shriver Z, Raman R, Venkataraman G, Drummond K, Turnbull J, Toida T, Linhardt R, Biemann
K, Sasisekharan R. Proceedings of the National Academy of Sciences. 2000; 97:10359–10364.
219. Xiao Z, Tappen BR, Ly M, Zhao W, Canova LP, Guan H, Linhardt RJ. Journal of Medicinal
Chemistry. 2010; 54:603–610. [PubMed: 21166465]
220. Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC,
Guglieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang Z, Robinson L, Buhse L, Nasr M,
Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G, Sasisekharan R. Nat
Biotech. 2008; 26:669–675.
221. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC,
Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S,
Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS,
Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. N Engl J Med. 2008
222. Porter A, Yue T, Heeringa L, Day S, Suh E, Haab BB. Glycobiology. 2010; 20:369–380.
[PubMed: 19946132]
223. Woods RJ, Tessier MB. Current Opinion in Structural Biology. 2010; 20:575–583. [PubMed:
20708922]
Robinson et al. Page 22
Electrophoresis. Author manuscript; available in PMC 2013 August 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Structural diversity of glycans
Based on their backbone structure, glycans can be broadly categorized as linear (GAGs) or
branched (N-linked and O-linked glycans). (A) O-linked glycans, attached to proteins via
covalent linkage typically to serine or threonine, can be subgrouped based on their core
glycan structures. (B) In N-linked glycosylation, the glycan is typically covalently linked to
asparagine on a protein containing the consensus sequence Asn-X-Ser/Thr, where X can be
any amino acid except proline. N-linked glycans generally display larger and more complex
structures than O-glycans but have less variability. All N-glycans share a common
trimannosyl core sugar structure and can be categorized into three types based on the nature
of monosaccharides extended from the core: high-mannose, complex, and hybrid. The
antenna structures displayed represent example extensions; typically a maximum of four
antennas with a bisecting N-acetylglucosamine exist for a given glycan. (C) GAGs, the
predominant group of linear glycans, are polymeric chains of sulfated disaccharide repeat
units consisting of an uronic acid linked to a hexosamine, which when linked to a protein are
termed a proteoglycan (protein and GAG). GAGs are classified based on the
monosaccharides making up their base disaccharide unit. Three examples are heparan
sulfate glycosaminoglycans (HS), chondroitin sulfate glycosaminoglycans (CS), and
dermatan sulfate glycosaminoglycans (DS).
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Figure 2. Major classes of acidic glycans that appear on N- and O-linked glycans in mammals
There are six monosaccharides that appear on the majority of acidic glycans. Mannose and
N-acetylneuraminic acid (along with N-glycolylneuraminic acid and 2-keto-3-deoxynononic
acid) primarily appear as glycoconjugates on proteins and lipids. Uronic acid and N-
acetylgalactosamine appear primarily on proteoglycans. N-acetylglucosamine and galactose
can appear in both glycoconjugates and proteoglycans. In the figure, a position labeled as X
is either sulfated or unsulfated, Y is either acetylated or sulfated (or in rare circumstances
unsubstituted), Z is either phosphorylated or not, A is either acetylated or not, and B
indicates the potential presence of a lactate residue.
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Figure 3. Framework for integrated analyses of glycan-protein interactions modulating influenza
A virus pathogenesis
Shown on the left is detailed structural characterization of target glycan receptors in the
human upper respiratory epithelia using a combination of lectin-staining (SNA, Sambucus
nigra agglutinin lectin) and detailed characterization using MALDI-MS. Shown on the right
is the validation of target glycan receptors by developing glycan array platforms comprising
of glycan motifs representing target structures. These platforms are used to screen and
determine quantitative relative binding affinities of different HAs and binding motifs are
validated using data mining platform with the guidance of X-ray crystal structure of HA-
glycan complexes.
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Figure 4. Structural determination of OSCS demonstrates the need for analytical integration
(A) Inspection of the disaccharide repeat units of heparin (top) and OSCS (bottom) indicate
the close structural similarity between the two. Heparin, a polydisperse mixture of
polysaccharide chains with an average length n, also has sequence diversity – the major
disaccharide unit is trisulfated. OSCS is also polydisperse, with polysaccharide chains of
average length m. However, all potential sites for sulfonation are “occupied” (degree of
sulfation [ds] = 4), such that there is no real sequence variability in OSCS. (B) The acetyl
signal for OSCS (ds=4) is readily distinct from that of heparin (δmethyl=2.12–2.16 compared
to 2.07ppm, respectively), yielding a sensitive signal for detection of OSCS within heparin.
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However, systematically changing the ds from 4 to 2.4 results in a shift in the methyl signal,
resulting in substantial overlap with the signal arising from heparin. (C) 500 MHz proton
spectra of (i) heparin alone or (ii) heparin spiked with 4% of alginate sulfate. The signals
arising from alginate sulfate are not distinguishable from those arising from heparin,
indicating that proton NMR is not a useful filter to detect alginate sulfate, if present within
heparin.
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Figure 5. Structural specificity in glycan-protein interactions
In the case of linear glycans such as GAGs, a distinct kink in the helical axis of the unbound
GAG chain is induced upon binding to protein such as fibroblast growth factor (FGF). The
kink provides optimal van der Waals contact and also positions the key sulfate groups for
optimal interactions with the protein. In the case of sialylated glycan receptors for influenza
HA, depending on the nature of the binding pocket across different HA subtypes, the glycan
receptor adopts a distinct umbrella-like topology spanning a fully open umbrella shape to
fully closed umbrella shape. The protein is shown as a surface colored in gray with glycan-
binding site colored in blue.
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Table 1
Challenges to the structure-function understanding of glycans.
Key challenge Features Impact on study of glycans
Glycan biosynthesis Nontemplate-driven process, unlike DNA/RNA and
protein
Replication- or translation-like ‘rules’ cannot be easily
applied; no direct methods to amplify glycans, unlike DNA
(PCR) and protein (recombinant expression)
Limited availability of glycans from natural sources
(e.g., cells, tissues)
Without amplification tools, analytical and functional methods
often require high sensitivity
Tissue-, developmental-, and metabolic-dependent
expression of glycan biosynthetic machinery
(glycosyltransferases and glycosidases)
Glycan structure is sensitive to cellular conditions, tissue type,
and developmental stages
Lack of proofreading in glycan biosynthetic process Increases structural diversity of glycans to be analyzed
Glycan structural
complexity and
heterogeneity
Presence of isomers and different anomeric
configurations
Properties generally not present in DNA and proteins;
challenges structural characterization by single method
Microheterogeneity – a range of glycan structures
(length, composition, branching) found at any given
glycosylation site on a glycoprotein
Highly similar physicochemical properties of glycan
microheterogeneities challenges their characterization
Branching Unambiguous designation of branches and their locations
challenged by analytical approaches
Presence of multiple modifications (sulfation,
acetylation, methylation) and high diversity of
linkages (location of linkages and anomericity)
Chemical synthesis is difficult and limited to small
oligosaccharides due to the need of complex protecting and
deprotecting strategies
Site of attachment to protein/lipid Requires glycan-protein and/or glycan-lipid characterization in
addition to glycan structure
Glycan presentation
and interactions
Presentation of an ensemble of different (often
related) structures within a biological system or
interaction
Studies must account for a population of glycans with similar
structures, rather than an ‘average’ single structure
Glycan-protein interactions often achieve high
affinity and specificity by multivalency
Correct presentation of glycan and glycan-binding protein/
domain(s) is critical for experimental design
Glycan-protein interactions modulate biology in an
analog-like nature
Functional readouts must be characterized in terms of
gradation of effects (not binary “on/off” effects)
High torsional flexibility of glycans mediates
presentation of a range of conformations for a
particular glycan
Sequence of glycan is often not sufficient to characterize
glycan-protein interactions; analysis of conformations and
topologies should be considered
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Table 2
Overview of analytical methods for glycan structural characterization
Method Structural information Strengths Weaknesses
MS Composition, profiling, chemical
modifications, glycosylation site
High sensitivity and accuracy, potential
for automation
Isomers indistinguishable, no
separation of complex
mixtures, quantification
difficult
MSn Sequence, linkages, chemical
modifications
Detailed structural information Significant expertise required,
low throughput
CE Profiling, separation High separation efficiency, can resolve
isomers, high throughput and automation,
complements MS analysis, amenable to
online connection with MS
Requires standards and/or
complementary techniques
(e.g., MS, enzymes) for
Unambiguous
characterization, limited
analyte capacity
HPLC Profiling, separation Multiple separation modes/stationary
phases, range of analyte capacity,
complements MS analysis, amenable to
online connection with MS
Requires standards and/or
complementary techniques
(e.g., MS, enzymes) for
Unambiguous
characterization
NMR Complete structure, stereochemistry Detailed structural information Significant expertise required,
low throughput, high amount
of sample material required
Lectin binding/arrays Structural motifs (terminal residues) Potential for high throughput, probe
glycans in their physiological context
Limited by availability and
specificity of characterized
lectins
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